EKR Therapeutics Raises Over $13 Million in a Series C Financing Round

EKR Therapeutics, Inc., a specialty pharmaceutical company focused on acquiring, developing, and commercializing proprietary therapeutics to enhance patient quality-of-life in the acute care setting, recently announced that it successfully raised over $13 million through the private placement of Series C preferred shares.

This financing round was led by Quaker BioVentures, a new investor in EKR. Quaker is a Philadelphia-based venture capital firm with approximately $500 million under management focused on investing in life science companies. Also participating were existing EKR investors NewSpring Capital, based in Radnor, Pa. and Short Hills, N.J., and ESP Equity Partners, a private investment company with operations in the U.S. and China.

Additionally, the Series C round included as new investors the Garden State Life Sciences Venture Fund, a $10 million fund dedicated to emerging life sciences companies in New Jersey and managed by Quaker BioVentures, and the Merrill Lynch Capital Healthcare Finance Group, a division of Merrill Lynch Business Financial Services Inc.

Adele C. Oliva, Partner at Quaker will join EKRs Board of Directors. Ms. Oliva was recently recruited to Quaker from Apax Partners where she was a Partner and co-led the U.S. Healthcare Group. Her extensive experience serving as a director for healthcare companies includes having served on the Board of ESP Pharma from its start-up in 2002 to its purchase in 2005 by PDL BioPharma (NASDAQ:PDLI) in a transaction valued at over $500 million. ESP Pharma was co-founded by Howard Weisman, EKRs Chairman and CEO.

Commenting on this announcement, Howard Weisman said, The success of EKRs financing activities has been very gratifying, and our ability to attract new investors, garner additional support from existing investors, and complete the Series C funding under favorable terms is a testimony to the strengths of our business plan.

He further noted, We are pleased to welcome Quaker as a new investor and I am personally delighted to be working again with Adele. Her business know-how and knowledge of the specialty pharmaceutical industry is extraordinary. I look forward to her contributions as a Board member.

According to Adele Oliva, Quakers healthcare investment strategy places significant importance on identifying and backing management teams with successful track records and clear strategies for growth. EKR fits these critically important criteria and I congratulate Howard on bringing together such a strong team, many who previously collaborated with him at ESP Pharma, said Oliva. EKRs focus on the acquisition and commercialization of specialty products for the acute care market is a growth model that is well known to Howard and his team. They have a clear, focused strategy and the proven ability to execute on it. I, too, look forward to again working with Howard and this energetic and seasoned group of professionals.

Since beginning operations in June 2006, EKR has evolved rapidly from a start-up to a solid commercial organization. In this relatively short period of time, the Company completed the acquisition of U.S. rights to its first product, Gelclair, recruited and deployed its own sales force, and in late 2006 began actively marketing Gelclair for the management of pain associated with chemotherapy and radiation induced oral mucositis/stomatitis.

Including this announced Series C round, EKR has to date successfully raised over $21 million in support of ongoing operations and potential product acquisitions. With regard to the latter, EKR has been actively engaged in pursuing its strategy of identifying product acquisition opportunities to leverage the Companys commercial strengths in the acute care market. The Company expects the new infusion of investment funds to facilitate continued favorable execution of its business strategy, thus, further fueling acceleration in EKRs long-term growth prospects.

EKR Therapeutics is a privately held specialty pharmaceutical company that has brought together a highly seasoned team of industry professionals. The Company focuses on the acquisition, development and commercialization of proprietary products for the acute care segment of the healthcare market, including oncology supportive care therapeutics. From its inception in late 2005, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care prescription products. EKRs goal is to be the pre-eminent provider of acute-care specialty products, backed by a commitment to excellence in customer service. EKR has investment support from key life science financing firms, including ESP Equity Partners, NewSpring Capital, and Quaker BioVentures.

For more information, please visit www.ekrtx.com